DIAGNOSTIC VALUE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN RHEUMATOID ARTHRITIS; COMPARED WITH IGM AND IGA RHEUMATOID FACTORS

2012 ◽  
Vol 2 (1) ◽  
pp. 36-44
Author(s):  
Dana Mohammed Tofiq ◽  
◽  
Khalida M. Mousawy ◽  
Raouf Rahim Mirza ◽  
◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Diagnostic Value ◽  
Rheumatoid Factors ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

scholarly journals Rheumatoid Factors: Clinical Applications

2013 ◽  
Vol 35 ◽  
pp. 727-734 ◽  
Author(s):  
Francesca Ingegnoli ◽  
Roberto Castelli ◽  
Roberta Gualtierotti
Keyword(s):  
Rheumatoid Arthritis ◽  
Healthy Subjects ◽  
Therapeutic Strategy ◽  
Clinical Applications ◽  
Rheumatoid Factors ◽  
Cyclic Citrullinated Peptide ◽  
Rheumatoid Factor Isotypes ◽  
Form Part ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

Rheumatoid factors are antibodies directed against the Fc region of immunoglobulin G. First detected in patients with rheumatoid arthritis 70 years ago, they can also be found in patients with other autoimmune and nonautoimmune conditions, as well as in healthy subjects. Rheumatoid factors form part of the workup for the differential diagnosis of arthropathies. In clinical practice, it is recommended to measure anti-cyclic citrullinated peptide antibodies and rheumatoid factors together because anti-cyclic citrullinated peptide antibodies alone are only moderately sensitive, and the combination of the two markers improves diagnostic accuracy, especially in the case of early rheumatoid arthritis. Furthermore, different rheumatoid factor isotypes alone or in combination can be helpful when managing rheumatoid arthritis patients, from the time of diagnosis until deciding on the choice of therapeutic strategy.

scholarly journals The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid Arthritis

2007 ◽  
Vol 26 (4) ◽  
pp. 285-288
Author(s):  
Ljubinka Damjanovska ◽  
Violeta Atanasovska ◽  
Todor Gruev
Keyword(s):  
Rheumatoid Arthritis ◽  
Diagnostic Value ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Mean Values ◽  
Cyclic Citrullinated Peptide ◽  
The Mean ◽  
Citrullinated Peptide ◽  
Peptide Antibodies ◽  
Latex Test

The Diagnostic Value of Anti-Cyclic Citrullinated Peptide Antibodies (anti-CCP) in Patients with Rheumatoid ArthritisA cross-sectional study was carried out to analyze the prevalence of anti-CCP antibodies and IgM RF in the sera of 160 randomly selected patients from the Rheumatology Department: 60 with RA, 50 with other rheumatic diseases (non-RA), 50 healthy controls (HC). The mean age of the group was 50.06+/-11.9 years. There were 141 females (88.1%) and 19 males (11.9%). RA patients fulfilled the revised ACR criteria. The mean duration of the disease was 82.4 months. Anti-CCP ELISA kit and IgM RF Latex test were used. The mean anti-CCP values were as follows: RA 60.4+/-57.6, non-RA 2.1+/-3.6, HC 1.3 +/-0.4 U/mL. Respectively, the mean values of IgM RF were: RA 515.8+/-525, non-RA 102+/-294, HC 15+/-57.5. Forty out of 60 (66.6%) RA patients were anti-CCP positive. Forty one out of 60 (68.3%) RA patients were positive for IgM RF. As expected, anti-CCP showed comparable sensitivity (66.8% vs. 68.3%) and higher specificity (98% vs. 87%) than IgM RF, at optimal cut-off values. The presence of either anti-CCP or IgM RF increased the testing sensitivity for the diagnosis of RA to 76.6%. AUC was greater for anti-CCP than for IgM RF (0.92 vs. 0.82).

scholarly journals Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis

2007 ◽  
Vol 8 (1) ◽  
Author(s):  
Ioannis Alexiou ◽  
Anastasios Germenis ◽  
Athanasios Ziogas ◽  
Katerina Theodoridou ◽  
Lazaros I Sakkas
Keyword(s):  
Rheumatoid Arthritis ◽  
Diagnostic Value ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

scholarly journals Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Rheumatoid Arthritis

2021 ◽  
Vol 106 (106(813)) ◽  
pp. 157-164
Author(s):  
R. Clavero-López ◽  
A.I. Navarro-Abad ◽  
M. Ruiz-Herance ◽  
J.M. Urra-Ardanaz
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Factor ◽  
Pharmacological Treatment ◽  
Test Validity ◽  
Reference Value ◽  
Diagnostic Value ◽  
Definitive Diagnosis ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

Introduction: For the diagnosis of Rheumatoid Arthritis (RA), the detection of the autoantibodies, rheumatoid factor (FR) and cyclic citrullinated peptide antibodies (APCC) are used. The presence of these antibodies determines that the RA is classified as seropositive or seronegative, with important implications both in the clinical development and in the prognosis of the disease. Objective: To assess the role of APCC and RF in the diagnosis of RA, as well as its influence on the establishment of pharmacological treatment. Methodology: We studied 213 patients with initial clinical suspicion of RA and with determinations of FR and APCC. Their definitive diagnosis and the pharmacological treatment established were studied. Results: 63 of 213 patients had a definitive diagnosis of RA. 77.8% were classified as seropositive. The sensitivity and specificity were higher in the APCC compared to FR. Initially the RF presented a low diagnostic value since it was negative in more than two thirds of the patients with a diagnosis of RA. The precise adjustment of its reference value allowed its use as a useful diagnostic tool. The presence of antibodies in patients with RA influences the treatment of choice with an increased use of Methotrexate against other immunosuppressants in seropositive patients. Conclusions: The APCC presented better parameters of diagnostic test validity than the RF. The presence of antibodies in RA influences the treatment of choice possibly due to the greater severity of the pathology.

Sign in / Sign up

Export Citation Format

Share Document